Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

Authors	PEARSON Andrew D J ROSSIG Claudia MACKALL Crystal SHAH Nirali N BARUCHEL Andre REAMAN Gregory RICAFORT Rosanna HEENEN Delphine BASSAN Abraham BERNTGEN Michael BIRD Nick BLEICKARDT Eric BOUCHKOUJ Najat BROSS Peter BROWNSTEIN Carrie COHEN Sarah Beaussant TERESA de Rojas EHRLICH Lori FOX Elizabeth GOTTSCHALK Stephen HANSSENS Linda HAWKINS Douglas S HORAK Ivan D TAYLOR Danielle H JOHNSON Courtney KARRES Dominik LIGAS Franca LUDWINSKI Donna MAMONKIN Maksim MARSHALL Lynley MASOULEH Behzad K MATLOUB Yousif MAUDE Shannon MCDONOUGH Joe MINARD-COLIN Veronique NORGA Koen NYSOM Karsten PAPPO Alberto PEARCE Laura PIETERS Rob PULE Martin QUINTAS-CARDAMA Alfonso RICHARDSON Nick SCHUESSLER-LENZ Martina SCOBIE Nicole SERSCH Martina A SMITH Malcolm A ŠTĚRBA Jaroslav TASIAN Sarah K WEIGEL Brenda WEINER Susan L ZWAAN Christian Michel LESA Giovanni VASSAL Gilles
Year of publication	2022
Type	Article in Periodical
Magazine / Source	European Journal of Cancer
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://www.sciencedirect.com/science/article/pii/S0959804921011709?via%3Dihub
Doi	http://dx.doi.org/10.1016/j.ejca.2021.10.016
Keywords	Paediatric oncology; CAR T-cell; Adoptive cellular immunotherapy; Paediatric Strategy Forum; Drug development; Cancer therapeutics
Description	The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), has been spectacular. However, currently, there are scientific, clinical and logistical challenges for use of CAR T-cells in BCP-ALL and other paediatric malignancies, particularly in acute myeloid leukaemia (AML), lymphomas and solid tumours. The aims of the Forum were to summarise the current landscape of CAR T-cell therapy development in paediatrics, too identify current challenges and future directions, with consideration of other immune effector modalities and ascertain the best strategies to accelerate their development and availability to children.